Literature DB >> 3499924

Electrophysiological action of bepridil on atrioventricular accessory pathways.

P Touboul1, G Atallah, G Kirkorian, P Lavaud, J R Kieny, M P Mathieu, A Dellinger.   

Abstract

The electrophysiologic properties of bepridil, a calcium channel blocker with additional effects on fast response tissues, were investigated in 10 patients with atrioventricular accessory pathways. Seven patients had Wolff-Parkinson-White syndrome, and three had concealed atrioventricular pre-excitation. A dose of 4 mg/kg was administered intravenously over five minutes. Bepridil increased the AH interval and the functional refractory period of the atrioventricular node. The effective refractory periods of the right atrium and right ventricle were also increased. Bepridil prolonged refractoriness in the accessory pathway both in the anterograde and retrograde direction. After bepridil administration it was impossible to induce reciprocating tachycardia electrically in two patients because of conduction block in the normal pathway. On the other hand, the zone of tachycardia was often increased after bepridil. Nevertheless, the heart rate during tachycardia was slowed by depression of conduction in both the normal and accessory pathways. The findings of this study provide a basis for the antiarrhythmic action of bepridil in patients with atrioventricular accessory pathways.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499924      PMCID: PMC1277263          DOI: 10.1136/hrt.58.4.333

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  17 in total

1.  Electrophysiological evaluation of the Wolff-Parkinson-White syndrome: problems in assessing antegrade and retrograde conduction over the accessory pathway.

Authors:  R H Svenson; H C Miller; J J Gallagher; A G Wallace
Journal:  Circulation       Date:  1975-10       Impact factor: 29.690

Review 2.  The preexcitation syndromes.

Authors:  J J Gallagher; E L Pritchett; W C Sealy; J Kasell; A G Wallace
Journal:  Prog Cardiovasc Dis       Date:  1978 Jan-Feb       Impact factor: 8.194

3.  Patterns of atrioventricular conduction in the human heart.

Authors:  A L Wit; M B Weiss; W D Berkowitz; K M Rosen; C Steiner; A N Damato
Journal:  Circ Res       Date:  1970-09       Impact factor: 17.367

4.  [A new antianginal drug, bepridil: efficacy estimation by exertion test during a double blind test against a placebo (author's transl)].

Authors:  J C Canicave; J Deu; J Jacq; R Paillet
Journal:  Therapie       Date:  1980 Sep-Oct       Impact factor: 2.070

5.  Blockade of myocardial slow channels by bepridil (CERM-1978).

Authors:  S Vogel; R Crampton; N Sperelakis
Journal:  J Pharmacol Exp Ther       Date:  1979-09       Impact factor: 4.030

6.  Atrial fibrillation in the preexcitation syndrome.

Authors:  R W Campbell; R A Smith; J J Gallagher; E L Pritchett; A G Wallace
Journal:  Am J Cardiol       Date:  1977-10       Impact factor: 2.778

7.  The role of premature beats in the initiation and the termination of supraventricular tachycardia in the Wolff-Parkinson-White syndrome.

Authors:  D Durrer; L Schoo; R M Schuilenburg; H J Wellens
Journal:  Circulation       Date:  1967-11       Impact factor: 29.690

8.  Supraventricular antidysrhythmic and electrophysiological effects of bepridil, a new antianginal agent.

Authors:  E Winslow; K A Kane
Journal:  J Cardiovasc Pharmacol       Date:  1981 Jul-Aug       Impact factor: 3.105

9.  Electrophysiologic effects and long-term efficacy of bepridil for recurrent supraventricular tachycardias.

Authors:  D Roy; M Montigny; G J Klein; A D Sharma; D Cassidy
Journal:  Am J Cardiol       Date:  1987-01-01       Impact factor: 2.778

10.  Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil.

Authors:  S Gulamhusein; P Ko; S G Carruthers; G J Klein
Journal:  Circulation       Date:  1982-02       Impact factor: 29.690

View more
  1 in total

1.  Electrophysiologic evaluation of antiarrhythmic drugs.

Authors:  P Touboul
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.